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Abstract
We examined the role of MALAT1, a highly conserved nuclear lncRNA, in chronic diabetic
complications affecting the heart and kidneys, specifically with respect to inflammatory
cytokine production. Endothelial cells, exposed to various glucose levels, and MALAT1
knockout mice and controls, with or without streptozotocin-induced diabetes were examined.
Endothelial cells cultured with high glucose, and renal and cardiac tissue from diabetic mice
showed increased inflammatory cytokine (eg. IL-6, IL-1β, TNFα) production along with
transient MALAT1 upregulation. This was confirmed by both transcript and protein analyses,
and such changes were prevented in the MALAT1 knockout diabetic animals. In the
MALAT1 knockout animals, diabetes-induced cardiac dysfunction was also prevented. We
further identified that such actions of MALAT1 are mediated by specific downstream
molecules including SAA3 and p53. The data from this study provided direct evidence to the
importance of MALAT1 in the pathogenesis of chronic diabetic complications involving the
heart and kidneys.

Keywords
MALAT1, Long non-coding RNA, Non-coding RNA, Diabetes, Inflammation, Endothelial
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Chapter 1
Introduction

1

1.1

Diabetes Mellitus

Diabetes mellitus is a chronic metabolic disease characterized by insulin deficiency. The
disease is divided into one of two broader subcategories, type 1 diabetes and type 2
diabetes. Type 1 diabetes results from absolute insulin deficiency due to specific autoimmune destruction of the pancreatic β-cells; therefore, the body loses the ability to
create and secrete insulin [1]. This is also classified as a type IV hypersensitivity reaction
as the autoimmune destruction is T-cell mediated [2]. In type 2 diabetes, there is no loss
of β -cells, but rather through poorly characterized mechanisms, patients develop a
resistance to their body’s insulin in important glucose-uptake organs such as the liver,
adipose, and skeletal muscle. Whether through destruction of islets in type 1, or
resistance to insulin in type 2, hyperglycemia results in diabetes through inadequate
glucose uptake into the tissues leading to excessive glucose in the circulation, which
leads to cellular damage. This chronic disease is both initiated and propagated by
inflammatory cells and cytokines which are elevated and sustained at a low-grade
throughout the disease [3]. Endothelial cells (ECs) are the principal cell type affected by
hyperglycemia due to their protective barrier function [4].

1.1.1

Epidemiology

Diabetes mellitus is one of the fastest-growing health issues in the world, affecting
around 400 million people worldwide, and is the seventh leading cause of death in the
USA [5].The incidence of diabetes increases with the obesity epidemic and is very
serious due to the increased risk for cardiovascular events, and the poor response to
interventions. It is also a tremendous burden on the healthcare system where it consumes
1of every 12 global health care dollars spent [6]. As a result of hyperglycemia in both
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type 1 and in type 2 diabetes, end-organ damage leads to significant mortality and
morbidity in the diabetic populations. Such end organ damage leads to afflictions of the
retina, kidneys, heart, and large blood vessels [7,8].

1.2

Diabetic Complications

Diabetic complications lead to functional and structural alterations through defects that
arise due to chronic hyperglycemia. Diabetic complications arise in most individuals with
diabetes, the complications themselves varying in degrees of severity [9,10].
Complications tend to occur later in the patient’s life due to the slow progression of
diabetes; however, complications can cause significant morbidity as well as mortality.
This thesis focuses on the major complications affecting the eye, kidney and heart.

1.2.1

Pathogenetic Mechanism

Despite the great differences and various tissues these complications affect, diabetic
complications stem from the same pathways, beginning with hyperglycemia and
oxidative stress. The four well studied pathways are the Hexosamine, Protein Kinase C,
AGE (Advanced Glycation End Products), and Polyol pathways [11,12]. Each of these
pathways culminates in an increase in oxygen radicals, which lead to oxidative stress.
These pathways lead to an increase in pro-inflammatory molecules such as tumor
necrosis factor alpha (TNFα), interleukin-six (IL-6), and interleukin eighteen (IL-18)
[13,14]. While each of these pathways and the inflammatory molecules have all been
studied in great detail in the context of diabetes, there is a knowledge gap in their
respective regulatory roles in the nucleus; therefore, understanding such processes could
provide novel insight into the progression of low grade chronic inflammation in diabetes.

The four pathways mentioned above are responsible for a dysregulation of the
mitochondrial electron transport chain and a subsequent overproduction of superoxide
and reactive oxygen species (ROS) [15]. Oxidative stress leads to endothelial dysfunction
that is a key development in diabetic microvascular disease [16]. This oxidative stress is
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the direct result of hyperglycemia, which greatly influences normal transfer of protons in
the mitochondria. Due to excess glucose going through glycolysis, and the formation of
pyruvate NADH and FADH2, the voltage across the inner mitochondrial membrane
increases which blocks electron transfer from complex III [17]. The overcharged
membrane stops pumping creating a halt in normal electron transport chain that leads to
molecular oxygen only accepting one electron from Coenzyme Q and the formation of an
O- anion [17.18]. This generates ROS at elevated levels and can lead to cell toxicity or
destruction of macromolecules. Very high levels of radical species can lead to DNA
damage and an increase in cell death in susceptible cells and tissues [19].

The presence of oxygen radicals also acts as a danger associated molecule pattern
(DAMP) which can be detected by innate immune receptors such as Toll-like receptors
(TLRs), and Nod-like receptors (NLRs) [20]. When activated, these receptors signal to
downstream transcription factors that increase production of inflammatory cytokines and
related proteins. The production of ROS in a single cell triggers the activation of internal
TLRs and NLRs. The activation of these receptors signals to downstream pathways
including interferon regulatory factor 3 (IRF3) and nuclear factor kappa B (NFκB) which
both translocate in to the nucleus and act as transcription factors for inflammatory genes.
This transcription leads to increased production and excretion of molecules like TNFα,
IL-6, and IL-1β, which influence development of inflammatory cells and promote a proinflammatory environment.

1.2.2

Diabetic Nephropathy

Diabetic nephropathy leads to functional and structural alterations of the kidney through a
variety of metabolic defects. At the transcriptional level damaged cells produce
vasoactive and fibrogenic factors changing renal structure and function and ultimately to
renal failure [21]. Diabetic nephropathy is the leading cause of renal failure in the
western world [22]. Microalbuminuria is an early manifestation in diabetic nephropathy
and leads to damage to glomeruli as well as hyperfiltration [23,24]. Later, patients
develop increasing proteinuria, reduced glomerular filtration rate and renal failure. As in

4

all diabetic complications, hyperglycemia is the most important factor leading to diabetic
nephropathy [21,24]. Hyperglycemia causes multiple metabolic defects which are
exacerbated by oxidative stress [21,24]. Glucose-induced EC dysfunctions result in
increased production of vasoactive factors, inflammatory mediators and extracellular
matrix (ECM) proteins [21,23,24].

1.2.3

Diabetic Retinopathy

Diabetic retinopathy is the leading cause of blindness in individuals under age 65 [9].
Likely as a result of the microvasculature of the eye, diabetic retinopathy is the most
commonly seen manifestation of diabetic microvasculature disease. Because of this, more
than 60 percent of diabetic individuals manifest some complication of damage of the
retina as a result of hyperglycemia. Diabetic retinopathy manifests in progressive stages:
Preclinical, non-proliferative, and proliferative retinopathy, each stage ranging from mild
to severe. Preclinical retinopathy is characterized by basement membrane thickening,
pericyte and EC loss [9,11,12,25]. Non-proliferative retinopathy is characterized by
venous dilatation, beading, hemorrhages and exudates, capillary non-perfusion, and intraretinal microvascular abnormalities [26]. Proliferative retinopathy is characterized by
neovascularization leading to retinal hemorrhages and retinal detachment [9,25,27].
Current therapies for retinopathy include anti-vascular endothelial growth factor (VEGF)
drugs as well as laser photocoagulation and burning of the blood vessels [28].

1.2.4

Diabetic Heart Disease

Cardiac complications account for the majority of diabetes related deaths [29].
Consequences related to cardiac affliction in diabetes include coronary atherosclerosis,
diabetic cardiomyopathy and autonomic neuropathy [30]. Coronary atherosclerosis
involves the narrowing of medium sized arteries due to the accumulation of plaque in the
intimal layer. Diabetics are more susceptible to atherosclerosis due to endothelial
dysfunction, which decreases nitric oxide production, as well as low-grade inflammation
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in the tissues that leads to increased levels of inflammatory cytokines like TNF-α and IL6 [31]. This alteration of the macrovasculature leads to ischemia and necrosis of the heart
tissue [32].

Autonomic diabetic neuropathy results from afflictions of the small vessels. Impaired
blood flow regulation in small capillary vascular beds decreases oxygen received by
tissues such as the heart and integumentary system. These individuals are more
susceptible for sudden cardiac death due to poor tissue perfusion [29,30].
Cardiomyopathy is a disease of the myocardium in patients with diabetes which is not
explained by coronary atherosclerosis. Rather, the complication is hallmarked by
impairment of the myocardial contractile properties, cardiomyocyte hypertrophy,
interstitial and perivascular fibrosis, myocyte necrosis and microangiopathic lesions such
as capillary basement membrane thickening [33].

1.2.5

Regulation of Gene Expression in Diabetes

Endothelial cells undergo a great number of transcriptional alterations in gene expression
to compensate for changes that arise due to diabetes and hyperglycemia [11,25]. Many of
these changes are attributed to oxidative stress, which is known to cause changes in cell
cycle regulation and survival. Due to an increase in DNA damage from ROS, checkpoint
regulator proteins are elevated to prevent mutations. P53 is such an enzyme that is
elevated in diabetes and leads to an increase in apoptotic cell death should DNA repair
pathways not resolve the problem. As such, proteins involved in break repair and
mismatch repair are also elevated including Artemis, DNA ligase IV, and replication
protein A [34,35].

Changes in gene expression are understandably accompanied by changes in chromatin
organization. DNA and histones are both modified through epigenetic changes to allow
for alterations in chromatin packing and accessibility to different genes [36,37]. One
example of this is the loss of heterochromatin following DNA damage by oxidative
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stress. Trimethylation at histone 3 lysine residue 9 (H3K9me3) is associated with
decreased gene expression at that locus although the same epigenetic modification at
other loci may have the opposite effect [38]. In diabetes, the loss of methylation at H3K9
leads to increased gene expression due to the loss of heterochromatin. Mice that were
diabetic on a db/db background (Mice with homozygous point mutations in the leptin
receptor) were found to have significantly decreased levels of H3K9me3 at inflammatory
gene promoters including IL-6 and monocyte chemoattractant protein-1 (MCP1).
However, the transcript and protein expression of these inflammatory cytokines were
significantly increased [39].

Another common epigenetic modification is the acetylation of histones. Acetylation of
lysines on histone 3 is more commonly associated with gene activation. However, to
some degree this is still regulated by the specific histone acetylases and histone
deacetylases, which are recruited to the site [37]. P300, a protein with a histone
acetyltransferase domain was found to be expressed at significantly higher levels in cells
treated with high glucose. This increase was accompanied by an elevated expression in a
number of potential downstream targets including ECM proteins and angiogenic factors
[40]. A separate study has also provided evidence suggesting that p300 may be involved
in increased NF-κB promoter activity [41].

In addition to histones, DNA can be directly modified in diabetes either through
epigenetics or through oxidative stress, leading to the formation of Hoogsteen or nonconventional base pair arrangements [42]. One common example are guaninequadruplexes, which occur in G-rich sequences. While certain transcription factors bind
with higher affinity to these structures, they also prevent proper chromatin arrangement
and inhibit heterochromatin formation. This leads to changes in gene expression
[42].ROS can also modify DNA through alterations in DNA methylation. DNA is
primarily methylated at target cytosines in CpG dinucleotide rich regions (CpG islands)
[43]. In healthy cells these CpG islands are frequently hypomethylated and lead to gene
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expression; however, many of these sites are hypermethylated in diabetes leading to
decreased expression of specific genes such as Sirtuin 1 (SIRT1), forkhead box P3
(FOXP3), and peroxisome proliferator-activator receptor gamma coactivator 1-alpha
(PPARGC1A) [44-46]. This is likely due to their G rich regions that are conducive to
forming guanine-quadruplexes as described above which greatly impair the activity of
demethylases [47]. DNA methyl transferases (DNMTs) and demethylases are the enzyme
classes responsible for the addition and removal of these methyl groups. Upon exposure
to ROS agents such as peroxide, DMNT1 binds with stronger affinity to chromatin,
specifically at CpG rich regions [48]. Furthermore, H2O2 treatment and damage triggers
the formation of a complex including DNMT1, SIRT1, and Enhancer of zeste 2 (EZH2),
which removes these proteins from their normal locations in the nucleus and further
repress gene expression [49].

Micro RNAs are also frequently altered in diabetic complications and have been shown
to play important roles. MiRNAs have been implicated in many relevant pathways in
diabetes from fat metabolism and cholesterol synthesis to insulin secretion and immune
cell recruitment [50, 51]. MiRNAs play important roles in proliferation, differentiation
and cell signaling, all of which are vital processes in diseases including diabetes [52, 53].
MiR-133 has been implicated in cardiomyopathy and diabetic nephropathy after it was
found to be aberrantly expressed in diabetic heart and kidney tissues [54]. MiR-200b
isoform has also been implicated in both diabetic retinopathy and cardiomyopathy where
it regulates VEGF [55.56]. The importance of miRNAs in diabetes is further supported
by studies using Dicer, an enzyme that is required in the biogenesis of miRNAs. Mice
deficient in Dicer have significant proteinuria, hyperfiltration, and damage to their
glomeruli, all of which are seen in diabetic kidney disease [57,58]. Our lab has previously
shown roles for multiple miRNAs in chronic diabetic complications. In this research, we
focus on long non-coding RNA.
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1.3

Non-Coding RNA

Most of the eukaryotic genome is transcribed yielding thousands of transcripts of varying
sizes; however, the vast majority of these transcripts have no protein-coding capacity
[59]. Non-coding RNAs (ncRNAs) were considered to be 'junk DNA' or ‘noise’ until
recently when it was discovered that they not only make up the majority of the human
genome, but many of them are highly conserved and functional [59-61]. NcRNAs are
RNA molecules of any size that are transcribed from DNA, but do not undergo
translation in to a stable product. In addition, many ncRNAs show cell type specific
expression, complex organizational patterns, and association with human diseases [5961]. General classes of ncRNAs include microRNA (miRNA), short interfering RNA
(siRNA), piwi-interacting RNA (piRNA), and long non-coding RNA (lncRNA [62,63].
The principal ncRNAs involved in pre and post-transcriptional regulation are further sub
categorized based on size. NcRNAs less than 30 nucleotides in length are termed short,
those ranging from 31 to 200 nucleotides are called medium, and those of length greater
than 200 nucleotides are classified as long ncRNAs [64]. All groups of ncRNAs have
been shown to serve a wide variety of functions in all tissues. Such functions include
heterochromatin condensing, histone modification, DNA methylation, gene silencing, and
protein organization [61,65,66].

1.4

Long non-coding RNA

LnRNAs are loosely defined as any RNA molecule which is greater than 200 nucleotides
and does not code for a functional protein product [67]. As such, the group is very diverse
containing molecules continuing 200 nucleotides to well over 10 thousand nucleotides.
Occasionally molecules once considered to be non-coding are found to code for a protein
which also changes which molecules are in this group. As such, there are still well over
4000 characterized unique lncRNAs in humans that make up both the majority of the
genome in percent composition of known transcripts, and total unique members
compared to any other group [64]. As with most genes, lncRNAs are frequently regulated
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both spatially and temporally by both the specific tissue or cell type, and the stage of
development.

1.4.1 Long non-coding RNA location in genome
LncRNAs are also found all across the genome on all chromosomes and can be
categorized based on their location. The five principal locational types of lncRNAs are
intronic, intergenic, antisense, bidirectional, and senses lncRNAs [68]. As the name
suggests, intronic lncRNAs are found in intronic regions of protein-coding genes and are
produced through alternative splicing of pre-mRNA. The can be on either the sense or
anti-sense strand or in the opposite direction as the protein-coding gene, but they do not
overlap with the protein coding gene [69]. Intergenic lncRNAs are located in distinct
transcriptional segments from coding genes. They have their own unique gene sites and
are at least 10kb removed from the nearest protein coding gene [65,69]. Antisense
lncRNAs are on the complementary sequence to the coding sense stand. They may
overlap with coding exons but their segments are spliced together to form a non-coding
product [70,71]. Bidirectional lncRNAs originate from divergent transcription from the
promoter of a protein-coding gene. As a result of this, they are usually very close in
proximity to, and on the opposite strand as the coding gene [69,72]. Sense lncRNAs
overlap the sense strand sequence of a protein-coding gene. The lncRNA can overlap a
portion of, or be entirely bound by the protein coding gene [72].

1.4.2 Long non-coding RNA Functions
In spite of their overwhelming prevalence, the functions of lncRNAs remain relatively
unclear. Even in cases where functionality is known, it is highly probable that due to their
sheer size they are capable of multiple diverse functions [73]. While they do not code for
proteins themselves, they are able to regulate protein and non-protein coding genes
through both -cis and -trans effects [74]. LncRNAs influence gene expression by
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signalling and regulating gene expression, act as decoys to inhibit specific interactions,
guiding proteins to specific chromatin sites, and scaffolding to organize and complex
molecules in specific cellular compartments [62,64,66]. Through these mechanisms and
potentially others, lncRNAs are able to influence a variety of cellular functions.
However, their role in diabetic complications remains under investigated. In the
following paragraphs I will discuss specific lncRNA relevant to this thesis.

1.5
1.5.1

MALAT1
Malat1 structure and conservation

MALAT1 (Metastasis associated lung adenocarcinoma transcript 1, NEAT2) was first
identified in 2003 in early-stage non-small cell lung cancer cells [75]. MALAT1 is found
on chromosome 11q13.1 where it encodes an 8.7 kb transcript. In mouse, it is found on
chromosome 19 and is slightly smaller at 6.98 kb though nearly 5kb are identical between
mouse and man and this high level of conservation is found in mammals. Regions of
MALAT1 can be found as far back in evolution as frogs and fish [76,77]. In addition to
not localizing to the cytoplasm, MALAT1 has no functional ORFs and lacks the ability to
bind ribosomes which have added to its classification as non-coding [74,76,78].

MALAT1 is encoded on a single exon and does not undergo any significant known
alterations, modifications, or splicing. The gene also encodes nearly no repeat elements.
Some studies have reported that a small 61-80 nucletotide RNA molecule is cleaved and
may enter the cytoplasm but remains untranslated [79,80]. This small RNA has been
called MALAT1-associated small cytoplasmic RNA (mascRNA). MascRNA seems to be
a likely candidate for a transfer RNA (tRNA) derived element [80]. This postulated
molecule is found at 3’ end of the MALAT1 RNA, anterior to the 3’ helix motif.
MALAT1 and its neighboring gene nuclear enriched abundant transcript 1 (NEAT1), have
been postulated to have arisen from a duplication event in the genome due to their unique
positions beside each other in the mammalian genome, and similar length [81]. However,
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MALAT1 and NEAT1 share almost no sequence homology beyond a small 3’ region [77].
(lncRNA) MALAT1 is highly stable for an RNA molecule with half-lives reported
between 9 and 24 hours [82]. Much of this stability is likely due to both its strict presence
in the nucleus where there is less overall degradation, as well as a stable triple helix
secondary motif at its 3’ terminus [68,83,84]. Because of this, there is also not ability for
this RNA to be polyadenylated [83]. In addition to its unique helix motif, MALAT1 has a
distinct sequence or secondary structure that allows it to localize to specific foci known as
paraspeckles [66]. At these nuclear speckles, MALAT1 complexes with other molecules
including its neighboring gene NEAT1 [66]. This secondary structure, along with its
tremendous length, makes MALAT1 a poor target for knockdown experiments which are
not sufficient to uncover a function for the lncRNA [85,86]. The gene’s expression can be
verifiably eliminated with the use of multiple zinc finger nucleases [85]. Mouse knockout
models of MALAT1 have been generated and are not only non-lethal, but also show no
observable phenotype, including the cells’ ability to form nuclear paraspekles [66,86]. To
date these models have only been used to study a small number of diseases and processes.

1.5.2

Malat1 function and interactions

MALAT1 is found at high levels in nearly all tissues and cells with some of the highest
reported in the colon, liver, immune cells, kidney, lung, brain, and heart. Because of this,
it remains to be seen whether MALAT1 exerts a single function in all tissues, or a tissue
specific role dependent on the tissue it is in. Several functions and interactions have been
found for this molecule with most of them involved in cancer, where it has been primarily
studied to date.

In cancer, MALAT1 has been shown to regulate metastasis and cell motility. As such,
MALAT1 had been reported to be elevated in many cancers including breast cancer,
cervical cancer, colorectal cancer, liver cancer, neuroblastoma, osteosarcoma, pancreatic
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cancer, prostate cancer, and gastric cancer [76,84,87,88]. In each of these cancers,
MALAT1 is associated with a poor prognosis, whereby as the level of transcript increases,
patient survival rate decreases [89]. Because of this MALAT1 has been termed an
oncogene [88,90]. One study has also proposed that MALAT1 is involved in the
alternative splicing and expression of other oncogenes [89,90]. MALAT1has also been
shown to be of importance in other diseases including pre-eclampsia, ischemia, and
sinoatrial node disease. One study also found elevated levels of MALAT1 in the
hippocampus, cerebellum, and brainstem of human alcoholics [91].

One of the most notable proteins involved in regulation of MALAT1 is p53. One study
found that when p53 was overexpressed MALAT1 levels decreased significantly [92]. A
considerably enriched p53 binding locus called BS-p53-1 was also shown to be enriched
in the MALAT1 promoter [92]. A separate study found a deletion of MALAT1 lead to
increased activation of p53 [93]. This association is further strengthened by numerous
studies that knockout or knockdown MALAT1 and report a decrease in proliferation and
cell survival [89]. MALAT1 knockdown cells also show higher sensitivity to apoptosis
inducing agents [89]. Together these findings suggest MALAT1 may be both regulated,
and a regulator of p53. This may help to explain MALAT1’s upregulation in diseases like
cancer where cell death is suppressed, but its downregulation in ischemia and other
disease characterized by chronic cell death.

Other functional roles for MALAT1 that have been reported include its ability to regulate
TGF-β signaling via SMAD2/3 [94]. In addition, it has been shown that MALAT1
regulates serum amyloid A3 (SAA3) [95]. SAA3 stimulates IL-6 and TNFα production
through NFκB. MALAT1 has also been shown to regulate its neighboring gene NEAT1
through cis interactions [66].

13

1.6

Rationale

Diabetic complications involve a large number of alterations to gene expression, all of
which are mediated through proteins and molecules resident in the nucleus. LncRNAs are
a relatively unstudied class of molecules, many of which are highly conserved and either
initiate or reside in the nucleus. We identified MALAT1 in a transcript array as a noncoding RNA which is aberrantly expressed in endothelial cells under hyperglycemic
stress [Figure 1]. MALAT1 is also one of the lncRNAs with the highest expression across
multiple tissues in mammals and is dysregulated in multiple diseases.
Preliminary work completed by our lab showed that MALAT1 expression is elevated at
specific points over a time course treatment of high glucose in endothelial cells.
Furthermore, the increase in MALAT1 transcript expression correlated with increases in
multiple proteins including inflammatory cytokines such as IL-6 and TNFα. Using
MALAT1 specific antisense oligonucleotides, MALAT1 levels were then reduced, and
this reduction correlated to a similar reduction in these inflammatory cytokines [95].
Recently, another study has confirmed this finding as well, showing that TNFα
expression in splenocytes was lower in mice lacking MALAT1 compared to WT mice
[96]. Based on these rationales, we developed the following hypothesis:

1.7

Hypothesis

MALAT1 is an important regulator of inflammatory cytokines in chronic diabetic
complications.
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1.8

Specific Aims

1. To investigate the role of MALAT1 in the production of inflammatory cytokines in
endothelial cells exposed to high glucose.
2. To investigate the role of MALAT1 in the production of inflammatory cytokines and
subsequent organ damage in mice with diabetes.

15

Chapter 2

2

Material and Methods

2.1

Animal Studies

Through collaboration with Dr. Spector (Cold Spring Harbor Laboratory, Cold Spring
Harbor, New York, USA), mice were obtained that have a ~3 kb deletion in the 5’ end and
promoter of the MALAT1 gene [66].This homozygous deletion is a global knockout
eliminating MALAT1 transcript expression in all tissues. The mice were generated on a
C57/BL6 background. Diabetes was induced in 10-week old mice using 5 injections of
low dose streptozotocin (STZ) (Sigma, Oakville, Ontario, Canada; 50 mg/Kg IP, Na
Citrate buffer, pH5.6) on consecutive days, controls receiving and equal volume injection
of buffer only [97]. Diabetes was evaluated based on a 4 hour fasting blood glucose level
greater than 20mmol/L. Control mice had glucose levels less than 10mmol/L. Mice were
all age matched and only male mice were used. The following groups of animals were
used: a) Non-diabetic control animals, b) STZ induced diabetic control animals c)
MALAT1 knockout mice, d) MALAT1 knockout mice with STZ- diabetes. All animals
were housed with access to standard diet (Harlan 2018 rodent diet) and water ad. Libitum.
Animals were monitored up until the time of sacrifice at either 1 week, 2 weeks, 4 weeks,
or 8 weeks post diabetes. Blood glucose levels, urine ketones, and body weight were
frequently recorded and monitored. Mice were euthanized by Forane™ (Baxter, Toronto,
Ontario, Canada) overdose and asphyxiation. Following sacrifice, blood, kidney, heart,
retina and other major organs were collected. Small portions of the tissues were snap
frozen for RNA and protein analyses and the remaining tissue fixed in 10% formalin to be
used for other experiments. All procedures were approved by the University’s Animal
Care Committee [97].
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2.2

Cell Culture

Human umbilical vein endothelial cells (HUVEC) and human retinal endothelial cells
(HREC) were purchased frozen from Lonza (Jackson, Wisconsin, USA), and Olaf
Pharmaceuticals (Worcester, Massachusetts, USA) respectively. Cells were grown at 37C,
5% CO2, in EBM-2 (Lonza) supplemented with 10% fetal bovine serum (FBS). Cells at
passages 4, 5, and 6 were used for experiments and were plated at a density of 2,500
cells/cm2. Once the cells had reached a confluency of 75%, they were serum starved for a
24-hour period. Following this, D-Glucose was used to stimulate cells at concentrations of
5ug/ml (Normal Glucose) or 25ug/ml (High Glucose). Cells were cultured for 6 hr, 12 hr,
24 hr, or 48 hr in the treated media before harvest for experiments [98].

2.3

RNA Isolation

Mouse tissue RNA extraction was carried out using the PureLink™ RNA Mini Kit
(Ambion Life technologies, Carlsbad, California, USA) and following the manufacturer’s
protocol. The tissues were homogenized in Lysis buffer using either a mechanical
homogenizer or a mortar and passage through a 20-gauge needle 4 times. An equal
volume of 70% (v/v) ethanol was added to the homogenized tissue and then the
homogenate was transferred to a spin cartridge to elute the liquid. RNA bound to the
membrane of the column was washed with included buffers before eluting with molecular
grade water. RNA purity and concentration were assessed with either a spectrophotometer
or a nanodrop measuring at 260 and 280 nm. RNA was then immediately reverse
transcribed to cDNA or kept at -70C.RNA extractions of HUVEC and HREC were carried
out with TRIzol™ Reagent (Invitrogen INC, Burlington, Ontario, Canada) following the
manufacturer’s instructions and as previously described [98].
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2.4

DNA Isolation and Gel Electrophoresis

DNA was extracted from mouse tail by a phenol-choloformextraction.A 1 cm piece of
tail was digested overnight in tail buffer using protinase K heated to 45 °C. DNA was
then extracted using phenol:choloform using a mixture of 25:24 (v/v). After vortexing
and centrifugation at 13,000 rpm, the supernatant was collected and DNA was then
precipitated via isopropanol and centrifuged again at 13,000 rpm for 10 minutes. The
supernatant was removed again and the DNA pellet was then washed with 70% ethanol
and spun down a final time. The ethanol was removed and any residual alcohol was left
to evaporate at room temperature. DNA was then reconstituted in deionized water and
stored at -20 °C to be used for genotyping. The sample purity was measured using the
ratio of ultraviolet absorbance at 260 and 280 nm. The DNA concentration was
determined measuring the absorbance at 260 nm.
DNA gel electrophoresis was used to validate the genetic knockout of MALAT1 in mice.
Two regions of MALAT1 were first amplified by PCR using primers specific to the
MALAT1 DNA sequence and flanked the cut site. DNA was amplified using TaqDNA
polymerase and PCR buffer (FroggaBio; North York, Ontario, Canada). Agarose gels
were prepared using 1.5% agarose in TAE buffer (10 nM Tris base, 0.5 mM EDTA, 4.4
mM acetic acid, pH 8.0). 3ul of Ethidium Bromide was added to create the gel. The wells
were loaded with 10ul of sample (8 ul DNA, 2 ul Loading buffer), a 1 kb DNA ladder, or
a negative control (no template). The electrophoresis was done in TAE buffer and run at
100 volts for 1.5 hours. Gels were visualized under ultraviolet light and photos were
taken.

2.5

LncRNA Array

RNAs were extracted using the RNAeasy miRNA isolation kit (Qiagen, Austin, TX)
according to the manufacturer’s instruction. Custom analysis of lncRNA expression
profiling from human retinal cells treated with high or normal glucose for 24 hours (n =
3/group) were performed by Asuragen Inc. (Austin, TX).
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2.5.1

LncRNA Array Protocol

Sample labeling and array hybridization were performed according to the Agilent OneColor Microarray-Based Gene Expression Analysis protocol (Agilent Technology) with
minor modifications. Briefly, mRNA was purified from total RNA after removal of rRNA
(mRNA-ONLY™ Eukaryotic mRNA Isolation Kit, Epicentre). Then, each sample was
amplified and transcribed into fluorescent cRNA along the entire length of the transcripts
without 3’ bias utilizing a mixture of oligo(dT) and random priming method (Arraystar
Flash RNA Labeling Kit, Arraystar). The labeled cRNAs were purified by RNeasy Mini
Kit (Qiagen). The concentration and specific activity of the labeled cRNAs (pmol Cy3/μg
cRNA) were measured by NanoDrop ND-1000. 1 μg of each labeled cRNA was
fragmented by adding 5 μl of 10 × Blocking Agent and 1 μl of 25 × Fragmentation Buffer,
then the mixture was heated at 60 °C for 30 min, and finally 25 μl 2 × GE Hybridization
buffer was added to dilute the labeled cRNA. 50μl of hybridization solution was dispensed
into the gasket slide and assembled to the LncRNA expression microarray slide. The
slides were incubated for 17 hours at 65 °C in an Agilent Hybridization Oven. The
hybridized arrays were washed, fixed and scanned with using the Agilent DNA
Microarray Scanner (part number G2505C).
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2.5.2

Array Data Analysis

Agilent Feature Extraction software (version 11.0.1.1) was used to analyze acquired array
images. Quantile normalization and subsequent data processing were performed using the
GeneSpring GX v12.0 software package (Agilent Technologies). After quantile
normalization of the raw data P/M filtration, lncRNAswere chosen for further data
analysis. Hierarchical Clustering was performed using the R software (version 2.15).

2.6

RNA in Situ Hybridization

RNA Fluorescent in situ Hybridization (FISH) was carried out using specific probes and
reagents designed by Stellaris™ RNA FISH (Biosearch Technologies, Petalume,
California, USA).To detect MALAT1 RNA, cells which were grown on coverslips were
rinsed briefly in PBS and then fixed in 2% formaldehyde in PBS for 10 mins at room
temperature (RT). Cells were made permeable in 70% (vol./vol.) Ethanol diluted in DEPC
treated water overnight at 4°C. Cells were washed in Wash Buffer A for 5 minutes prior to
hybridization. Hybridization was carried out using Stellaris™ RNA FISH probes
dissolved in TE buffer to a concentration of 12.5 uM. Hybridization buffer was then used
to dilute the probe to a working concentration of 125 nM and incubated with the cells in a
moist chamber at RT for 4-6 hr. For nuclear visualization, cells were rinsed with Wash
Buffer A and Wash Buffer B, and nuclei were then counterstained with Hoechst Stain
(5ng/mL) for 30 minutes in the dark at RT. Coverslips were then mounted on slides to be
visualized by immunofluorescence [99].
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2.7

cDNA synthesis and Quantitative RT-PCR

For real-time quantitative PCR (Q-PCR), first 1ug of total RNA was reverse transcribed to
cDNA using High Capacity CDNA Reverse transcription Kit (Applied Biosystems Inc.,
Foster City, California, USA). The kit used a MultiScribe™ reverse transcriptase enzyme,
as well as random oligo hexamers to amplify all RNA. Gene-specific primers sets were
designed using NCBI basic local alignment program (BLAST) or ordered pre-designed
from Qiagen (Toronto, Ontario, Canada), Q-PCR was carried out in duplicate using SYBR
Green Master Mix (Clontech, Mountain View, California, USA) and run using a
LightCycler™ 96 (RocheDiagnotstics Canada, Laval, Quebec, Canada)5. SYBR Green is a
dye that binds to double stranded DNA and fluoresces, allowing for detection of all double
stranded products in each cycle. Target genes were analyzed using standard curves to
determine relative levels of gene expression. Molecular grade water was used to make up
the volume difference in both the negative control, and no RT control. The levels of
specific RNAs were analyzed using the Roche LightCycler™ 96 System. Individual RNA
samples were normalized according to the level of β-actin [55]. All sequences for reverse
and forward primers used are summarized in Table 2.1.

2.8

ELISA

Proteins were isolated from mouse tissue using radioimmunoprecipitation assay buffer.
Protein concentration was then measured using a BCA protein assay kit (Pierce, Rockford,
Illinois, USA). Protein concentrations were kept constant across protein lysates used for
ELISA. For detection of IL-6 and INFγ in tissue homogenate, pre-coated plates were
obtained from R&D systems (Minneapolis, Minnesota, USA) and the protocol was
followed to the manufacturer’s instructions. Plates were measured at 450 and 570 nm (to
correct for plate defects) using a plate reader. For detection of albumin and creatinine in
mouse urine, Albuwell™ and Creatinine Companion kits were ordered from Exocell
(Philadelphia, Pennsylvania, USA) [95].
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Table 2.1: Oligonucleotide sequences for Real-Time PCR
Gene

Primer sequences (5’ – 3’)

Hsa/Musb ACTB

F: TGTGGATCAGCAAGCAGGAG
R: TGCGCAAGTTAGGTTTTGTC

Hs MALAT1

F: TCTTAGAGGGTGGGCTTTTGTT
R: CTGCATCTAGGCCATCATACTG

Hs TNFA

F: AGGCGCTCCCCAAGAAGACAG
R: AGCAGGCAGAAGACGTGGTG

Hs IL6

F: GGGGCTGCTCCTGGTGTTG
R: CTGAGATGCCGTCGAGGATGTA

Hs IL1B

F: GCGGCATCCAGCTACGAATCT
R: GGGCAGGGAACCAGCATCTT

Mus MALAT1

F: TGGGGGAGTTGTAGGCTTCT
R: GGAGTGAGGCTTGTGGTAGG

Mus NEAT1

F: TGGCCCCTTTTGTTCATTAGC
R: TGGAAGGCCATTGTTTCAGG

Mus P53

F: CTCCCTTGCTGTAGGTAGCG
R: CGTCGATGCAGTGAGGTGAT

Mus SAA3

F: TGACAGCCAAAGATGGGTCC
R:TCCGGGCAGCATCATAGTTC

Mus TNFA

F: AGGCACTCCCCCAAAAAGAT
R: CACCCCGAAGTTCAGTAGACAG

Mus IL1B

F: TTCAGGCAGGCAGTATCACTC
R: GAAGGTCCACGGGAAAGACAC

Mus IL6

F: ACAACCACGGCCTTCCCTACTT
R: TCATTTCCACGATTTCCCAGAG

a

Hs, Human, bMus, mouse. F, forward primer; R, reverse
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2.9

Cardiac Ultrasound Imaging

Echocardiographic and Doppler studies were performed using the Vevo™ 2100 imaging
system (Visualsonic, Toronto, Ontario, Canada). All data were performed 1 week prior to
the time of sacrifice between 1 and 5 PM. Each mouse was anesthetized in a sealed
chamber with inhalant isolfuorane at 3% in 100% oxygen. Once anesthetized, the mouse
was transferred and secured on its dorsal side to a heated imaging platform and isofluorane
was maintained at 1% for the duration of the experiment. The hair of the mouse chest was
carefully removed, and an electrode gel was applied to the chest before placing the
transducer to the left of the sternum. At this position, images were obtained of the left
ventricle along its long axis. The blood flow velocity was measured using Doppler
ultrasonography to directly measure the flow motion (Pulse Wave Doppler). M-mode
tracings of the heart were acquired by rotating the transducer to be perpendicular to the
left ventricle and aligned along the short axis of the heart. Measurements were averaged
from 3 consecutive cardiac cycles [55,100].

2.10

PhyloCSF

To measure the coding potential of MALAT1 and other gene transcripts, we used the
previously established codon substitution frequencies (CSF) method to evaluate the
evolutionary characteristics in their alignments with orthologous regions in other
sequenced mammalian genomes [101,102]. CSF generates a likelihood score for a given
sequence considering all codon substitutions observed within its alignment across multiple
species, which was based on the relative frequency of similar substitutions occurred in
known coding and noncoding regions. CSF compares two empirical codon models; one
generated from alignments of known coding regions and the other according to noncoding
regions, producing a log odds likelihood ratio reflecting which model better explains the
alignment. The source code and executables are freely available at
http://compbio.mit.edu/PhyloCSF.
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2.11

Statistical Analysis

All experimental data are expressed as mean ± SEM and were analyzed by ANOVA
followed by Student’s t-test. Differences are represented as significant as values of
p<0.05.
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Chapter 3

3

Results

3.1

Screening for a potential LncRNA of interest

Initially, we performed a custom microarray analysis (Arraystar) to identify lncRNA
changes. To this extent, we exposed human retinal endothelial cells (HRECs) to high or
normal glucose treatment for 24 hrs. MALAT1was identified as a gene, which was
dysregulated in high glucose compared to normal glucose treatment. Extracted RNAs
were sent for quantitation by array analysis, which was designed to detect a large number
of human lncRNAs. MALAT1 was identified as one of many lncRNAs that was
downregulated when HREC cells were cultured in high glucose compared to cells
cultured in low glucose [Figure 3.1].
This finding from the array was then tested in HUVECs where we cultured the
cells in high and low glucose. Using qRT-PCR it was found that levels of MALAT1 were
significantly elevated at 48 hours of high glucose (25µM) treatment compared to cells in
normal glucose (5µM) treatment [Figure 3.2]. Since MALAT1 is highly expressed in
nearly all tissue types, it is likely to have tissue specific functions. Furthermore, the
targets of MALAT1 included molecules of interest in the context of diabetic
complications including SAA3, p53 and VEGF.. Hence, alterations in MALAT1
expression in different cell types made MALAT1 a promising candidate gene for follow
up studies.
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Figure 3.1: LncRNA Array Analysis
Total RNA was isolated from HRECs cultured for 24 hours in high gluose (25 mM) or
normal glucose (5 mM) media and sent to Aiglent Technology. mRNA was purified from
total RNA after removal of rRNA and each sample was amplified and transcribed into
cRNA using a mix of oligo(dT) and random priming. cRNAs were further purified
following which slides were assembled and RNA was hybridized to a lncRNA array. After
incubation, slides were fixed and scanned with using the Agilent DNA Microarray
Scanner. Agilent Feature Extraction software was used to analyze acquired array images.
Subsequent data processing was performed using the GeneSpring GX v12.0 software
package. Hierarchical Clustering was performed using the R software. Array probes were
sequenced through BLAST and MALAT1 was identified as a lncRNA downregulated
more than 3 fold in the HG compared to NG treated HRECs [n=3 per group, data
displayed as means, data points in red indicate statistical significance.]
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Figure 3.2: MALAT1 expression in HUVEC
Real time RT-PCR analysis of MALAT1 expression in HUVECs. Cells were exposed to
25 mM (HG) or 5 mM (NG) glucose over a time course of 48 hours. Levels of MALAT1
transcript were significantly increased in HG treated HUVEC at the 48 hour mark
compared to the NG HUVEC. [* p<0.05 compared to NG, experiment performed in
triplicate from three separate experiments, data (as a ratio to β-actin) expressed as mean ±
SEM].
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3.2

3.2.1

MALAT1 as a gene of interest

MALAT1 is a bona fide long non-coding RNA

Before taking our interest in MALAT1 to a higher organism, we first set out to
investigate MALAT1 as a gene. Using bioinformatics software PhyloCSF we confirmed
that MALAT1 is a non-coding RNA [Figure 3.3]. PhyloCSF uses amino acid
arrangement and substitution frequencies in evolution to generate an odds likelihood
ration upon whether the sequence is better explained as a coding sequence or a noncoding model. This is performed without the necessity of the sequence being similar to
known proteins in current databases [101]. We compared it to known coding genes, as
well as other non-coding genes. MALAT1 was identified as being 1011 times more likely
to be explained by a non-coding than a coding model. No segment of MALAT1 was
better explained by the coding model than the non-coding, and the greatest value was 102
for a stretch of less than 35 nucleotides. Other non-coding genes were better explained by
the non-coding model, and known coding genes were best explained by the coding model
as was expected. This finding strongly suggests that MALAT1 is a non-coding transcript.
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Figure 3.3: CSF scores
Codon Substitution Frequencies (CSF) scores of TUBB, END1, SOX2, RGNEF, RAG1,
TGFB2, Malat1, Mir133b, and Mir34a RNA. PhyloCSF reports scores in decibans or
log-ratio of whether a transcript is better explained by a coding or non-coding model. A
score of 32 indicates a transcript is 1032 times more likely to be explained by the coding
model than non-coding model, whereas a score of -11 would indicate a transcript is 1011
times more likely to be explained by the non-coding model than the coding model.
PhyloCSF does not rely on homology of known coding sequences but rather evolutionary
amino acid substitution as well as missense and nonsense substitution frequencies.
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3.2.2

MALAT1 is present in the nucleus and is upregulated by
glucose

Following confirmation of its lncRNA status, we looked at MALAT1 in HRECs using
FISH to view the localization of MALAT1 in the cell. Using specific probes we located
MALAT1 in the cells. Such analysis showed the presence and organization of MALAT1
in the nucleus. Our findings revealed that MALAT1 is an exclusively nuclear molecule
and localizes to specific domains in the nucleus, which are known as paraspekles [Figure
3.4]. MALAT1’s inability to leave the nucleus provides further evidence that it is not a
coding gene.
We further used RT-PCR to look for differences in MALAT1 expression in
HRECs to compare and validate our findings in HUVECs with a different cell type. As
most of the diabetic complications under investigation are due to microvascular damage,
capillary endothelial cells are of great interest in determining potential alterations of
MALAT1 expression under high glucose conditions. RT-PCR expression of MALAT1 in
HREC cells was consistent with our HUVEC experiment and showed a significant
increase of MALAT1 in HREC cells at the 48hr time point when cells were treated with
high glucose compared to control cells. Compared to normal glucose-treated cells,
MALAT1 expression after 48hrs in the high glucose treatment was doubled. To examine
potential downstream effects of MALAT1 upregulation, we examined several
inflammatory cytokines. Under high glucose, these inflammatory cytokines are normally
elevated compared to normal glucose conditions, and in diabetes this elevation leads to
chronic levels of low grade inflammation. To this extent, we examined TNFα, IL6 and
IL-1β. These are well established molecules that are upregulated in response to glucose in
the context of chronic diabetic complications [103-105].We used qRT-PCR to quantify
the expression of specific pro-inflammatory genes in the HREC cells.Expression of these
genes increased in high glucose treatment compared to normal-glucose, and like
MALAT1, this increase was significant in all tested genes at the 48-hour mark [Figure
4.5].
These findings taken together with literature on MALAT1 in other diseases and tissue
expression made MALAT1 a promising candidate gene to look at in an in vivo model.
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Figure 3.4: FISH visualization of MALAT1 lncRNA localization

MALAT1 is a completely nuclear retained lncRNA. Malat1 probes were used to detect
presence of malat1 in HRECs using fluorescence. Cells that had been cultured in high
glucose (25 mM) or normal glucose (5 mM) for 48 hours were hybridized with probes for
MALAT1 RNA (red) then counterstained with Hoechst (Blue). Images were merged
(purple) to show completely nuclear and speckled arrangement of MALAT1 lncRNA in
the nuclei. No visual differences could be seen between HG and NG.
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31

H R E C M a la t1
H R E C IL -1 

*

4

5

HG

HG
IL 1  :  - a c t in R N A

M a la t 1 :  - a c tin R N A

NG
3

2

1

*

4

3

2

1

0

0

6hr

12hr

24hr

6hr

48hr

12hr

24hr

48hr

T im e

T im e

H R E C - IL -6

HREC - TNF

2 .5

HG
NG

2 .0

1 .5

1 .0

0 .5

0 .0

*

6

HG
T N F  :  - a c t in R N A

*
IL 6 :  - a c t in R N A

NG

NG
4

2

0

6hr

12hr

24hr
T im e

48hr

6hr

12hr

24hr

48hr

T im e

Figure 3.5: MALAT1 and inflammatory cytokine expression in HREC

Real time RT-PCR analysis of MALAT1, IL-1β, TNFα, and IL-6 expression in HRECs
exposed to 25 mM (HG) or 5 mM (NG) glucose over a time course of 48 hours. All four
genes are significantly upregulated in HG treated HRECs at 48 hours compared to NG. [*
p<0.05 compared to NG, experiment performed in triplicate from three separate
experiments, data (as a ratio to β-actin) expressed as mean ± SEM].
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In Vivo Results

3.3

3.3.1

Clinical monitoring of Mice

MALAT1 knockout mice were generated by Dr. Spector using a C57/BL6 background
[66]. Animals were obtained and the genetic background was confirmed using DNA
genotyping [Figure 3.6]. Control mice on a C57/BL6 background were obtained from
Charles River to be used as controls. Diabetes was confirmed in mice by measurement of
blood glucose levels. Diabetic animals were hyperglycemic (>20.0 mmol/L glucose) and
had reduced body weight gain compared to control animals [Figure 3.7]. Diabetic animals
also showed polyuria, and glucosuria. None of the animals had measurable levels of
ketones (data not shown). Loss of MALAT1 lncRNA had no effect on either the blood
glucose level or the bodyweight gain and knockout animals showed no differences in
urine output.
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Figure 3.6: Genotype confirmation of MALAT1-/- mice

Analysis of MALAT1 genotype by PCR from tail DNA. Results indicate MALAT1 wildtype (+/+) and homozygous null (-/-) mice. DNA was resolved on a 1.5% agarose gel and
imaged using UV light. A DNA ladder ranging from 100 to 1000 bp is shown in lane 1.
Included base pair sizes denote predicted sizes for the KO and WT bands.
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Figure 1.7: Clinical monitoring
Blood glucose values and body weights of mice during the follow up period. Mice were
injected with STZ for five days following which they were checked for hyperglycemia
(Time 0). Mice were examined regularly for 8 weeks. Both wild-type (WT) diabetic (Dia)
animals, and MALAT1-/- (MALAT1 KO) animals were hyperglycemic compared to
control animals at all time points and had reduced body weight gain. Loss of MALAT1
lncRNA had no significant effect on hyperglycemia or body weight gain in diabetes.
[n=8-13; data expressed as mean ± SEM].
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3.3.2

Diabetes alters MALAT1 expression in tissues

Using Real time PCR, MALAT1 transcript levels were measured in the heart, kidney and
retina of WT control, WT diabetic, MALAT1 KO control, and MALAT1 KO diabetic
animals. MALAT1 expression showed initial elevation in the kidneys from WT diabetic
animals, followed by a decrease at 2, 4, and 8 weeks compared to the WT control tissue
[Figure 3.8]. Both the kidney and heart tissue had significantly decreased levels of
MALAT1 RNA in the WT diabetic animals compared to the WT control animals after
two months of follow-up. [Figure 3.9]. There was no significant alteration in MALAT1
expression in B6 mouse retinal tissue at 2 months. MALAT1 KO animals were devoid of
MALAT1 expression at all time-points in all tissues.
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Figure 3.8: MALAT1 expression in diabetes over two months

Real time RT-PCR analysis of malat1in wild type (WT) control, WT diabetic (Dia),
MALAT1-/- (MALAT1 KO) control, and MALAT1-/- diabetic mouse tissues. Transcript
levels of MALAT1 RNA were significantly elevated in diabetic mouse kidney tissue at 1
week, following which it was reduced compared to the WT control mouse kidney tissue.
[*p<0.05 compared to WT control; n=3-13; data (as a ratio to β-actin) expressed as mean
± SEM, normalized to controls].
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Figure 3.9: MALAT1 expression in heart, kidney, and retina at 2-months

Real time RT-PCR analysis of malat1 in wild type (WT) control, WT diabetic (Dia),
MALAT1-/- (MALAT1 KO) control, and MALAT1-/- 2-month diabetic mouse kidney,
heart and retinal tissue. Transcript levels of MALAT1 were significantly decreased in
diabetic mouse heart and kidney tissue compared to the WT controls. MALAT1 RNA
was not present in any of the knockout tissues. MALAT1 expression was not
significantly altered in the retinal tissue. [*p<0.05 compared to WT control; n=6-13; data
(as a ratio to β-actin) expressed as mean ± SEM].
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3.3.3

MALAT1 regulates inflammatory cytokine expression the
tissues of chronically diabetic animals.

Having both confirmed that MALAT1 lncRNA levels are altered in diabetes in our in
vivo model, as well as having confirmed our MALAT1 KO model, we tested for
transcripts with changes in expression that might be attributed to the loss of MALAT1
RNA in diabetes. We focused on kidney and heart tissues first due to the availability of
tissue.
Using RT-PCR, we measured the inflammatory cytokine transcript levels of IL1β, IL-6 and TNFα in both 1 and 2-month heart and kidney tissue. IL-1β and TNFα
transcript abundances were upregulated in the WT diabetic animals compared to WT
controls in both heart and kidney at both time points [Figures 3.10, 3.11, 3.12, and 3.13].
IL-6 was upregulated in both heart and kidney tissues at the 1-month time point, and
kidney tissue at the 2-month time point in WT diabetics compared to WT controls. Loss
of MALAT1 prevented diabetes induced increase of inflammatory transcripts in both
heart and kidneys after both one and two months of diabetes.

39

1 -M o n th H e a r t - T N F 

T N F  :  - a c tin R N A

2 .5

B 6 W T - C o n tro l

*

M a la t1 K O - C o n tro l

2 .0

B 6 W T - D ia
1 .5

M a la t1 K O - D ia

1 .0

#
0 .5

0 .0

1 -M o n th H e a r t - IL 1 

1 -M o n th H e a r t - IL -6
4

2 .5

*

B 6 W T - C o n tro l

IL 6 :  - a c t in R N A

M a la t1 K O - C o n tro l

2 .0

B 6 W T - D ia
1 .5

M a la t1 K O - D ia

1 .0

#
0 .5

0 .0

IL 1  :  - a c t in R N A

B 6 W T - C o n tro l

*

M a la t1 K O - C o n tro l
3

B 6 W T - D ia
M a la t1 K O - D ia

2

#
1

0

Figure 3.10: Inflammatory transcript expression at 1-month diabetes in heart tissue

Real time RT-PCR analysis of TNFα, IL-6, and IL-1β in wild type (WT) control, WT
diabetic (Dia), MALAT1-/- (MALAT1 KO) control, and MALAT1-/- 1-month diabetic
mouse cardiac tissues. All three transcripts were significantly increased in diabetic mouse
heart tissue compared to the WT controls. Loss of MALAT1 RNA prevented such
increases in the MALAT1 KO diabetic group. [*p<0.05 compared to WT control;
#p<0.05 compared to WT Dia; n=8-13; data (as a ratio to β-actin) expressed as mean ±
SEM, normalized to controls].
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Figure 3.11: Inflammatory transcript expression at 1-month diabetes in kidney tissue

Real time RT-PCR analysis of TNFα, IL-6, and IL-1β in wild type (WT) control, WT
diabetic (Dia), MALAT1-/- (MALAT1 KO) control, and MALAT1-/- 1-month diabetic
mouse renal tissue. All three genes were significantly increased in diabetic mouse kidney
tissue compared to the WT controls. Loss of MALAT1 lncRNA prevented such increases
in the MALAT1 KO diabetic group. [*p<0.05 compared to WT control; #p<0.05
compared to WT Dia; n=6-10; data (as a ratio to β-actin) expressed as mean ± SEM,
normalized to controls].
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Figure 3.12: Inflammatory transcript expression at 2-month diabetes in heart tissue

Real time RT-PCR analysis of TNFα, IL-6, and IL-1β in wild type (WT) control, WT
diabetic (Dia), MALAT1-/- (MALAT1 KO) control, and MALAT1-/- 2-month diabetic
mouse cardiac tissue. All three genes were significantly increased in diabetic mouse heart
tissue compared to the WT controls. Loss of MALAT1 lncRNA prevented such
increases in the MALAT1 KO diabetic group for both IL-1β and TNFα but not for IL-6. .
[*p<0.05 compared to WT control; #p<0.05 compared to WT Dia; n=8-13; data (as a
ratio to β-actin) expressed as mean ± SEM, normalized to controls].
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Figure 3.13: Inflammatory transcript expression at 2-month diabetes in kidney tissue

Real time RT-PCR analysis of TNFα, IL-6, and IL-1β in wild type (WT) control, WT
diabetic (Dia), MALAT1-/- (MALAT1 KO) control, and MALAT1-/- 2-month diabetic
mouse renal tissue. All three transcripts were significantly increased in diabetic mouse
kidney tissue compared to the WT controls. Loss of MALAT1 lncRNA prevented such
increases in the MALAT1 KO diabetic group. MAlAT1 KO control mice had
significantly less expression of all three genes than the WT control mice. [*p<0.05
compared to WT control; #p<0.05 compared to WT Dia; n=4-9; data (as a ratio to βactin) expressed as mean ± SEM, normalized to controls].
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3.3.4

Protein expression

This finding was then further confirmed using protein extract from kidney and heart. We
used ELISAs to test for levels of the pro-inflammatory cytokines IL-6 and INFγ in tissue
lysates from both heart and kidney and IL-1β in kidney. Our findings corroborated those
of our transcript analyses and showed significant elevation in inflammatory cytokine
production in WT diabetic animals, and protection from this increase in the MALAT1
knockout diabetic animals for each of the cytokines tested in both tissues [Figures 3.14
and 3.15].
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Figure 3.14: Inflammatory cytokine expression in 2-month heart tissue

ELISA for mouse IL-6 and INFγ in wild type (WT) control, WT diabetic (Dia),
MALAT1-/- (MALAT1 KO) control, and MALAT1-/-diabetic 2-month cardiac tissue.
Both cytokines were significantly increased in diabetic mouse heart tissue compared to
the WT controls. Loss of MALAT1 lncRNA prevented such increases in the MALAT1
KO diabetic group. MALAT1 KO control mice had comparable expression to WT
control mice. [*p<0.05 compared to WT control; #p<0.05 compared to WT Dia; n=5-9;
data expressed as mean ± SEM].
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Figure 3.15: Inflammatory cytokine expression in 2-month kidney tissue

ELISAs for mouse IL-6, IL-1β, and INFγ in wild type (WT) control, WT diabetic (Dia),
MALAT1-/- (MALAT1 KO) control, and MALAT1-/- diabetic 2-month renal tissue. All
three cytokines were significantly increased in diabetic mouse kidney tissue compared to
the WT controls. Loss of MALAT1 lncRNA prevented such increases in the MALAT1
KO diabetic group. MALAT1 KO control mice had comparable expression to WT
control mice. [*p<0.05 compared to WT control; #p<0.05 compared to WT Dia; n=5-9;
data expressed as mean ± SEM].
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3.3.5

Potential interactions of MALAT1

We looked at multiple genes of interest that may be involved in MALAT1 regulation or
downstream of MALAT1. Three candidate genes were SAA3, NEAT1, and p53. SAA3, a
regulator of inflammation, has previously been shown to be diminished in MALAT1 KO
mice [66]. Our study supports this finding, as well as provides new evidence for
MALAT1’s regulation of SAA3 using diabetic animals. SAA3 was found to be
significantly elevated in the WT diabetic animals, but loss of MALAT1 lncRNA
prevented this increase in both heart and kidney [Figures 3.16, 3.17]. We further
examined two other potential molecules regulated by MALAT1 as proposed by literature,
these being NEAT1 and p53. NEAT1 is the neighboring gene of MALAT1 and is also an
evolutionary conserved lncRNA [83]. Neat1 was also shown to be elevated in the liver
and brain cortex of MALAT1 knockout mice compared to WT animals in a previous
study [66]. While diabetes had no significant effect on neat1, we confirmed that loss of
MALAT1 led to significant increases in the transcript compared to WT animals in both
the heart and kidney tissues [Figures 3.14, and 3.15]. P53 has been investigated as both
an upstream as well as a downstream mediator of MALAT1 [89.92,93]. At 2-months post
diabetes in the heart tissue, p53 transcript was significantly elevated compared to WT
control animals, and this increase was attenuated in the MALAT1 KO diabetic animals
[Figure 3.14]. However, in the kidney tissue, both MALAT1 KO groups and the diabetic
WT animals had significantly elevated levels of p53, suggesting a tissue specific altered
regulation [Figure 3.17].
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Figure 3.16: Molecular alterations downstream to malat1 knockout in 2-month heart tissue

Real time RT-PCR analysis of SAA3, p53, and neat1in wild type (WT) control, WT
diabetic (Dia), MALAT1-/- (MALAT1 KO) control, and MALAT1-/- 2-month diabetic
mouse cardiac tissues. SAA3 was not found to be significantly altered in diabetes.
Relative abundance of p53 was significantly increased in the WT diabetic animals. Loss
of MALAT1 lncRNA prevented such increases in the MALAT1 KO diabetic group.
Neat1 transcript abundance was significantly increased in both MALAT1 KO groups.
[*p<0.05 compared to WT control; #p<0.05 compared to WT Dia; n=6-10; data
expressed (as a ratio to β-actin) as mean ± SEM, normalized to controls].
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Figure 3.17: Molecular alterations downstream to MALAT1 lncRNA knockout in 2-month kidney tissue

Real time RT-PCR analysis of SAA3, p53 and Neat1 in wild type (WT) control, WT
diabetic (Dia), MALAT1-/- (MALAT1 KO) control, and Malat1-/- diabetic 2-month
diabetic mouse renal tissue. SAA3 was significantly increased in diabetic mouse kidney
tissue compared to the WT controls. Loss of malat1 prevented such increases in the
MALAT1 KO diabetic group. P53 was significantly increased in the WT diabetic mice as
well as both MALAT1 KO groups compared to the WT controls. Transcript abundance of
neat1 was significantly increased in both the MALAT1 KO groups compared to the WT
control mice. [*p<0.05 compared to WT control; #p<0.05 compared to WT Dia; n=4-9;
data (as a ratio to β-actin) expressed as mean ± SEM, normalized to controls].
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3.4

Functional Analyses

Renal and cardiac functional analyses were performed for both the kidneys and the heart
to assess the effect of diabetes on target organ damage and whether such changes are
specifically mediated through MALAT1 and other biochemical alterations.

3.4.1

Albumin Creatinine Ratio (ACr ratio)

ACr ratio was used to assess kidney function over the course of one day. This is a
standard test for assessing kidney function [106,107]. Albumin is a large protein that is
normally only present in the urine in very small quantities due to its large size being
unable to pass through the glomeruli. In diabetes however, damage to the kidney by
glucose-induced alterations leads to widening in pore sizes, which allows larger proteins
to pass through and further damage the kidney. As such, albuminuria is one of the earliest
and most characteristic functional changes in diabetic nephropathy [108]. Creatinine on
the other hand is a protein compound that is released regularly over the course of a day as
a by-product of normal muscle breakdown [109]. Lower as well as higher than normal
creatinine levels have both been associated with diabetes; however, in most cases the
levels do not appear to be altered in diabetes due to similar skeletal muscle abundances in
diabetic and non-diabetic animals [110,111]. Briefly, two days before sacrifice, urine was
collected for 24 hours and the total volume was recorded. Urine samples were kept and
frozen in -80 °C to be used in future analyses. ELISAs were used independently to
measure the amount of albumin and creatinine in the urine samples, the ratios were
obtained, and were normalized to 24 hr urine volume. The WT diabetic as well as the
MALAT1 KO diabetic animals showed significantly increased ACr ratio compared to the
WT control animals [Figure 3.18]. Loss of MALAT1 lncRNA had no effect on the ACr
ratio in MALAT1 KO control animals.
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Figure 3.18: Mouse 24 hr albumin: creatinine ratio in 2-month diabetic mice
Urinary albumin/creatinine ratio measured in in wild type (WT) control, WT diabetic
(Dia), MALAT1-/- (MALAT1 KO) control, and MALAT1-/- diabetic mice following 2
months of STZ-induced diabetes. Diabetic animals had significantly higher
albumin/creatinine ratios compared to the control animals. MALAT1 had no significant
effect in reducing the diabetes-associated increase. [*p<0.05 compared to WT control;
n=8-10; data expressed as mean ± SEM].
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3.4.2

Doppler Echocardiography

In the heart, echocardiography was used to look at and measure blood flow in the left
ventricle, as well as heart wall thickness. We used the VEVO2100 ultrasound to carry out
this procedure 5 days prior to sacrifice. In diabetes, the heart loses some of its
contractility due to changes in the cardiomyocytes. This causes normal blood flow
patterns to be altered which can be measured using pulsewave Doppler [112]. The E/A
wave ratio is one metric used to look at the amount of blood that moves through the
mitral valve during normal filling of the left ventricle. In normal hearts, the majority of
the blood moves in to the ventricle during the E (early) wave and a smaller remaining
amount is pushed into the heart by arterial contraction in the A (late) wave. However, in
diabetes, only about half the blood moves into the heart in the diastolic filling or E wave,
and much more blood has to be pushed through during the A wave leading to a lower E/A
ratio. Both MALAT1 control and WT control animals showed normal E/A ratios [Figure
3.19]. WT diabetic animals had significantly decreased E/A ratios, indicating some
diastolic dysfunction. Loss of MALAT1 in diabetic animals had partial protective effect
on diabetes induced dysfunction. Supplemental data can be found in Table 3.1.
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Figure 3.19: Loss of MALAT1 prevents functional alterations in heart contractility in
diabetes

Using a Vevo2100 ultrasound we conducted echocardiographic examinations to assess
functional changes in heart contractility of MALAT1-/- ( MALAT1 KO)control, WT
diabetic (Dia) and MALAT1-/- diabetic mice compared to wild-type (WT) control mice.
2-month WT diabetic mice showed reduced E/A ratio compared to WT control animals.
Such changes were partially corrected in the MALAT1 knockout diabetic animals.
MALAT1 knockout control animals showed no differences in E/A ratio compared to WT
control animals. [*p<0.05 compared to WT control; #p<0.05 compared to WT Dia;
compared to WT control; n=8-12; data expressed as mean ± SEM].
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Table 3.1:Echocardiographic data

Variable

WT-Co

MALAT1-Co

(n=6)

(n=6)

WT-Dia
(n=6)

MALAT1-Dia
(n=6)

Diastolic Function
E’/A’ ratio

1.585±0.155

1.675±0.141

1.29±0.103

1.410±0.132

401±16

391±35.57

430±40.40

410±31.12

Haemodynamics
Heart rate
(beats/min)

Note: WT-Co, wild type control; WT-Dia, wild type diabetes; MALAT1-Co; MALAT1
knockout control, MALAT1-Dia; MALAT1 knockout with diabetes.
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Chapter 4

4

Discussion

This study looked at the role of MALAT1 in producing inflammatory cytokines in
chronic diabetic complications. Here we have examined a novel mechanism that takes
place in diabetes to regulate the production of inflammatory cytokines using a long noncoding RNA. Furthermore, this is the first study to look at MALAT1 in a chronic diabetic
animal model. This study expands on the current knowledge of diabetic complications
and immune transcript regulation in the nucleus, and provides novel insight and findings
in the field of lncRNA.
Inflammation is a key process in the development of diabetic complications
[13,14]. High glucose in the blood initially leads to the impairment of glycolytic
metabolism and an increase in reactive oxygen species in the cells. Oxidative DNA can
then act as a danger-associated signal which can be recognized by internal receptors
which trigger the production of these inflammatory molecules [34,35]. Low-grade
chronic inflammation is continuously present in sites that are affected by the disease. This
leads to a pro-inflammatory environment and recruitment of larger than normal numbers
of inflammatory cells which mediate many of the pathologies associated with diabetic
complications [13,14]. These conditions lead to continual damage to the inflamed tissues
due to the secreted molecules and actions taken by the immune cells. Inflammation is
also a key process involved in cancer metastasis where levels of MALAT1 RNA are
greatly elevated. MALAT1 was also previously shown to be involved in the regulation of
inflammatory cytokines in other systems [66,95].
We identified MALAT1 as one of many lncRNAs that was upregulated in
endothelial cells when exposed to high glucose using an array. Using a local alignment
tool, probe sequences were compared across the human genome and one was identified as
a complete 60-nucleotide match identical to human MALAT1. In this case, MALAT1
lncRNA was downregulated almost 3-fold in the human retinal endothelial cells
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compared to the control treated cells.

However, when we examined cells using RT-PCR to validate the array findings
we were surprised to see a duration dependent alteration of glucose induced MALAT1
expression. Although in keeping with array study, it was downregulated after 24hrs,
following 48hrs of high glucose, it was increased. We confirmed these findings in two
endothelial cells and then explored further effects of such upregulation. The exact reason
for such variability is not clear. Several explanations may be put forward. The sensitivity
of the assay (array vs. RT-PCR), and RNA degradation may both be in part responsible.
In addition, other factors induced secondary to oxidative stress may also be responsible.
Nevertheless, the biological significance of such alterations were demonstrated following
siRNA mediated silencing [95].
MALAT1 is one of the more characterized lncRNAs although it still remains
largely unstudied due to its relatively recent discovery in 2003 [75]. Several papers have
proposed functions or mechanisms for the molecule, but there is little consensus and
novel findings continue to be reported. A likely reason for this may be due to tissue
specific or cell-specific functions. MALAT1is expressed at high levels in nearly all cell
types but it is quite possible that it does not exert the exact same function in each cell
[89]. MALAT1 lncRNA is an extremely large molecule at 8.7 kb in humans, so it is even
more likely that the molecule has multiple functions in a given cells rather than just one.
MALAT1 is highly conserved evolutionarily [92], so it is possible that MALAT1 may
have evolved to have a specific function that only presents itself under a particular stress.
MALAT1 has been shown to be a true lncRNA [84]. It was shown recently that
about five percent of proposed lncRNAs actually coded for small peptide sequences
[103]. Several others are still debated due to their homology to protein coding transcripts
or strong association with ribosomes. MALAT1 has been shown to be a long noncoding
RNA through multiple means including bioinformatics analyses, localization, ribosomal
affinity, and in vitro transcription-translation assays [78, 66]. Such assays use both
biotechnological and quantitative experiments to look at the affinity of the transcript for
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ribosomes, and the presence of specifically sized bands matching open reading frame
(ORF) sizes in Western blots. We have also confirmed this ourselves using the
bioinformatics software PhyloCSF which found MALAT1 RNA to be 1011 times to be
better explained by a non-coding transcript model than a coding model. This software is
also highly used and recognized due to its coding which allows it to not only consider
known protein sequences but account for the possibility of uncharacterized or unknown
sequence arrangements [101,102].
Here we further show MALAT1 lncRNA is an exclusively nuclear lncRNA which
again supports its classification as a lncRNA. This finding has been shown by other labs
previously [66,86]. We do, however show that MALAT1 lncRNA localization in the
nucleus does not appear to change under high glucose treatment. Using florescent probes
specific to MALAT1 RNA we were able to show that (lncRNA) MALAT1 retains its
focal expression pattern under both high and low glucose treatments in endothelial cells.
No visual differences could be seen between HG and NG using this method, which is
why RT-PCR analysis was conducted to show changes in MALAT1 expression more
sensitively.
We looked at MALAT1 expression levels and we compared levels of transcripts
of interest using qRT-PCR in the high and low glucose treated cells. We first found that
at 48-hours, MALAT1 was upregulated more than two fold in the high glucose treated
cells compared to normal glucose treated cells. However, MALAT1 expression was not
significantly different between the treated cells and controls at 6, 12, or 24 hours. This
same pattern was identified in both HREC and HUVEC cells.
Many transcripts have altered expression under high glucose treatment in
endothelial cells and this is well documented [11,25]. Many genes involved in
angiogenesis, the extra cellular matrix, repair and death pathways are elevated. Of
particular interest to us though were the pro-inflammatory transcripts. These molecules
such as IL-6, TNFα, IL-1β, and INFγ are involved in the initiation as well as sustaining
an inflammatory response [13,14]. We found that the expression of these transcripts
under high glucose closely matched the expression of MALAT1 in endothelial cells. Our
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lab has shown previously that siRNA mediated silencing of MALAT1 prevented such
upregulation of inflammatory molecules [95]. We then decided to look at MALAT1
using an animal model of diabetes to better understand its role in vivo. We also focused
on the key process of inflammation.

To accomplish this, we obtained a MALAT1 deficient model through a
collaboration with Dr. Spector [66]. This model and its development have been described
previously, but briefly, it is a phenotypically normal mouse on a C57/BL6 background
and is completely devoid of (lncRNA) MALAT1 in all tissues. There are no defects in
breeding and the animals live past 2 years of age without intervention. The knockout was
achieved with the excision of a roughly 3-kb segment that includes the MALAT1 5’
promoter. Two genes which were reported to be abnormally expressed at the transcript
level in both the brain cortex and liver of the animals were SAA3 and NEAT1 [66].
NEAT1 is the neighboring gene of MALAT1 and is also a lncRNA. These two molecules
are both highly conserved and nearly always located side by side, despite being on
different chromosomes in different species including in mouse and rat. NEAT1was found
to have increased expression in the analyzed tissues in the MALAT1 knockout mouse
[77]. SAA3 is a gene involved in the regulation of inflammatory molecules. It is normally
expressed at high levels in the liver but in the MALAT1 knockout model, its expression
was significantly decreased. This finding combined with our finding of a decreased
inflammatory marker in MALAT1 KO mice, combined with our increased inflammatory
markers in HG treated cells which also had increased expression of MALAT1 led us to
focus on a role for the MALAT1 lncRNA in the regulation of inflammatory molecules.

We only used male mice in this study as we were not looking for gender specific
differences at this time and did not want to include additional variables to the study.
Diabetes was induced in animals at 10 weeks of age using STZ. We used four different
time points in this study of 1, 2, 4, and 8 weeks of diabetes. Loss of MALAT1 had no
effect on blood glucose levels and all groups of diabetic animals had nearly identical
blood glucose levels both before and after STZ induced diabetes. Additionally, loss of
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MALAT1 had no effect on polyuria or glucosuria in the diabetic animals. While diabetic,
MALAT1 knockout animals did not lose the same amount of body weight as their agesex- matched controls. We focused on the heart and kidney due to their abundant tissue
supply and importance in two major diabetic complications.
MALAT1 expression in the heart and kidney tissues of WT diabetic mice was
initially increased but then significantly decreased at 2, 4 and 8 weeks of diabetes. This
finding was somewhat confusing. In the cell culture system, we found that high glucose
caused increased MALAT1 expression in endothelial cells 48 hours after incubation with
high glucose. Several possible explanations may be put forward. Tissues contain multiple
cell types which interact with each other. Our initial cell culture studies were performed
in HUVECS and HRECS where we showed glucose-induced MALAT1 upregulation.
However, previous studies on other molecules have reported cell specific variations under
the same conditions. Despite endothelial cells being the principal cell influenced by
hyperglycemia, other cell types make up a larger portion of the tissues and could
influence MALAT1 lncRNA levels. Moreover, direct extrapolation from cell culture in
to tissue may not always be feasible. The data however, are in keeping with our array
data, which showed downregulation of MALAT1 after 24 hours. Nevertheless, such an
increase in MALAT1 expression in diabetes was sufficient to trigger inflammatory
cytokine expression as evidenced by the inhibition of such changes in the knockout mice.
It is of interest to note that in the WT diabetic mice, this initial upregulation of MALAT1
was capable of a sustained effect. The changes in MALAT1 expression from 2 to 8 weeks
may indicate the possibility of a compensatory mechanism, whereby the system attempts
to decrease MALAT1 expression to reduce the presence of inflammatory cytokines. An
alternative possibility would be MALAT1 induction of an epigenetic regulatory change.
Such a change would be inducible by the increase in MALAT1 transcript and then
sustained even if MALAT1 RNA levels dropped off later [EPI]. The exact mechanism of
MALAT1’s regulation and action in the nucleus in producing such changes remains to be
explained.
At both 1 and 2-months, inflammatory transcript levels were increased in the WT
diabetic animals as was expected and has been previously reported. However, an exciting
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finding was that in both heart and kidney tissues at both 1 and 2-months of diabetes,
inflammatory transcript levels were not elevated at all and were maintained at WT
control or even under WT control animal levels in the MALAT1 KO mice. This
suggested that loss of MALAT1 had a protective effect, which inhibited the increased
normally seen in diabetes.
This finding was then further supported by the examination of protein levels from
2-month animal tissues. These findings closely matched those of our transcripts where
the significant increases in pro-inflammatory molecules associated with diabetes were
prevented in the diabetic MALAT1 knockout animals. We further went on to look at
functional differences and consequences this change in inflammatory status might have
using the albumin: creatinine ratio from urine taken from the animals, and using
echocardiography data that had been collected prior to sacrifice.
E/A ratio which is a measurement of left ventricular diastolic function was
significantly decreased in WT diabetic animals indicating some dysfunction; however,
this decrease was attenuated in the MALAT1 knockout diabetic animals again supporting
our findings that the loss of MALAT1 has a protective effect. Despite this, we determined
using the previously collected urine that the ACr was not significantly different between
the WT and knockout diabetic animal groups. All values for albumin concentration,
creatinine concentration, and 24-hour urine output were similar for the two groups
leading to no significant differences between them. This suggests that the damage to the
glomeruli in filtration due to diabetes may be more detrimental to the kidneys than the
loss of MALAT1 can compensate for. Alternatively, MALAT1 activity may not
contribute as significantly to kidney dysfunction as heart dysfunction. The differential
effect of MALAT1 inhibition on renal and cardiac function may also suggest possible
tissue specific pathogenetic roles of this molecule.
We also examined a few different mechanisms and interactions MALAT1 may
have with other molecules. Three of these molecules were neat1, SAA3, and p53.
NEAT1 is the neighboring gene of MALAT1 and changes in its expression may reflect
limitations and compensations in our animal model that we need to address. In a previous
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study, NEAT1 has also been shown to have a regulatory role in diabetic retinopathy [76].
As in the case of Zhang et al., we found NEAT1 levels to be significantly elevated in our
two knockout MALAT1 mouse groups, suggesting that the molecules might regulate in –
cis [66]. Neat1 expression did not however appear to change in diabetes. Neat1 has been
looked at recently as a potential regulator of inflammatory molecules in cells so it is
possible that MALAT1 exerts a regulatory role on NEAT1 or visa-versa. The molecules
may also compensate to some degree as their functions remain largely unknown. Dual
knockout MALAT1 and NEAT1 mice have not yet been attempted and may provide a
phenotype which the two individual knockouts on their own seemingly lack.
MALAT1 has previously been shown to regulate SAA3 in mice, as well as
inflammatory cytokines in cells induced with hyperglycemia [66,95]. Here we validate
those findings but use a diabetic animal model to show that this mechanism involving
MALAT1 holds true in vivo and in multiple complex organs. As with the other
inflammatory molecules, SAA3 transcript expression was increased in the WT diabetic
animals, and this increased expression was eliminated in both the heart and kidney tissues
at both the 1 and 2-month time points.
Unlike in cancer where MALAT1 lncRNA levels are found to be at extremely
high levels [76,82,87], here we have found an initial surge of MALAT1 RNA, followed
by decreased expression. One reason we speculate this might be due to a compensatory
mechanism where the cells attempt to decrease the amount of inflammatory cytokines
being produced by reducing expression of MALAT1. Another potential mechanism
involves p53 feedback which is completely absent in cancer, but found at elevated levels
in diabetes. In this system, p53 appeared to be a downstream target of MALAT1. These
data are in keeping with past research by other investigators. A third reason could be due
to functional redundancy with other RNA transcripts such as its neighboring gene
NEAT1. While we did see a decrease in inflammatory cytokine expression, it is possible
other effects of the loss of MALAT1 were compensated for by other molecules. Due to
its size and high basal expression levels in most tissues , the potential number of
interactions MALAT1 can have is quite substantial so uncovering more about the
regulatory process is essential to understanding more about MALAT1’s mechanism.
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MALAT1 could also have tissue dependent functions that carry, though here we are able
to show consistent suppression of inflammatory molecules in tissues that have lost
MALAT1 expression.

4.1

Future Studies

Here we have identified MALAT1 as an intermediary molecule in the
transcriptional pathway involved in producing inflammatory cytokines in diabetic tissues.
MALAT1 is already known to be important in other diseases and pathologies, but its
mechanism is largely unknown. Despite this, MALAT1 is not essential for life or
development in vivo and its lack of coding potential and strong conservation between
species make it a good candidate for RNA based therapies.
MALAT1 is still relatively unstudied at this point and there are many more follow-up
studies need to uncover its function in diabetes, as well as in normal healthy tissues.
In this study we have shown MALAT1 is initially upregulated and then downregulated in
the type-1 STZ-induced diabetic mouse model, but taking this study in to a type 2
diabetic model such as the db/db mouse, or other diabetic model would help validate our
findings or even provide novel insights in MALAT1 function. Using a different animal
model of diabetes might also allow us to uncover stronger associations between
MALAT1 and its downstream targets. Additionally, looking at later time-points such as 4
and 6 months after the onset of diabetes would potentially be able to show a stronger
protective effect on reducing inflammatory cytokines and protecting cardiac function due
to the gradual progression and worsening of complications in the WT-diabetic mouse.
In this study we have focused on afflictions of the heart and kidney, but other tissues such
as the retina and cerebral cortex might also provide novel insights in to the effects of
MALAT1 in other tissues. We also noticed differences in the heart and kidney with
respect to functional differences after the loss of MALAT1 in diabetes. Conducting cell
specific studies for these tissues using podocytes or cardiomyocytes might help to
understand these differences.
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Whether MALAT1 lncRNA has the same effect in all tissues, or enters a tissue specific
function remains unclear. Future work on the function of MALAT1 and its role in
diseases like diabetes will improve our understanding of why this lncRNA has such high
levels of expression and strong evolutionary conservation, potentially paving the way to
new discoveries in the large family of lncRNA.
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